Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1880 2
1886 1
1911 3
1914 1
1915 3
1916 1
1917 5
1922 1
1928 1
1930 1
1935 1
1936 1
1940 1
1942 1
1943 2
1945 1
1947 1
1948 4
1949 1
1950 1
1951 2
1952 3
1953 5
1954 5
1955 5
1956 6
1957 4
1958 8
1959 4
1960 10
1961 9
1962 12
1963 12
1964 11
1965 13
1966 12
1967 24
1968 27
1969 15
1970 29
1971 33
1972 30
1973 28
1974 33
1975 21
1976 23
1977 24
1978 28
1979 43
1980 41
1981 50
1982 51
1983 57
1984 55
1985 39
1986 47
1987 41
1988 34
1989 40
1990 52
1991 54
1992 48
1993 42
1994 49
1995 30
1996 69
1997 40
1998 47
1999 53
2000 43
2001 44
2002 33
2003 31
2004 34
2005 40
2006 56
2007 47
2008 53
2009 62
2010 49
2011 61
2012 57
2013 71
2014 80
2015 79
2016 82
2017 79
2018 76
2019 80
2020 79
2021 95
2022 64
2023 76
2024 71
2025 66

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,877 results

Results by year

Filters applied: . Clear all
Page 1
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J; BILCAP study group. Primrose JN, et al. Among authors: fox rp. Lancet Oncol. 2019 May;20(5):663-673. doi: 10.1016/S1470-2045(18)30915-X. Epub 2019 Mar 25. Lancet Oncol. 2019. PMID: 30922733 Free article. Clinical Trial.
Secondary Progressive Multiple Sclerosis: New Insights.
Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, Murphy N, Lassmann H. Cree BAC, et al. Among authors: fox rj. Neurology. 2021 Aug 24;97(8):378-388. doi: 10.1212/WNL.0000000000012323. Epub 2021 Jun 4. Neurology. 2021. PMID: 34088878 Free PMC article. Review.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Engineering a memory with LTD and LTP.
Nabavi S, Fox R, Proulx CD, Lin JY, Tsien RY, Malinow R. Nabavi S, et al. Among authors: fox r. Nature. 2014 Jul 17;511(7509):348-52. doi: 10.1038/nature13294. Epub 2014 Jun 1. Nature. 2014. PMID: 24896183 Free PMC article.
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial.
Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE; DISCOMS investigators. Corboy JR, et al. Among authors: fox rj. Lancet Neurol. 2023 Jul;22(7):568-577. doi: 10.1016/S1474-4422(23)00154-0. Lancet Neurol. 2023. PMID: 37353277 Clinical Trial.
Cortical foot.
Fox R, Sztriha L. Fox R, et al. Pract Neurol. 2020 Aug 28:practneurol-2020-002544. doi: 10.1136/practneurol-2020-002544. Online ahead of print. Pract Neurol. 2020. PMID: 32859691
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Among authors: fox rj. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
2023 International Rome consensus for the nomenclature of Sjögren disease.
Ramos-Casals M, Baer AN, Brito-Zerón MDP, Hammitt KM, Bouillot C, Retamozo S, Mackey A, Yarowsky D, Turner B, Blanck J, Fisher BA, Akpek EK, Baldini C, Bootsma H, Bowman SJ, Dörner T, Laing L, Lieberman SM, Mariette X, Pflugfelder SC, Sankar V, Sisó-Almirall A, Tzioufas AG, Anaya JM, Armağan B, Bombardieri M, Carsons S, de Vita S, Fox RI, Gerli R, Giacomelli R, Gottenberg JE, Hernández-Molina G, Jonsson R, Kruize A, Kwok SK, Li X, McCoy SS, Ng WF, Olsson P, Rischmueller M, Saraux A, Scofield RH, Valim V, Vitali C, Vivino F, Wahren-Herlenius M, Moutsopoulos HM; International Task Force on Nomenclature of Sjögren Disease. Ramos-Casals M, et al. Among authors: fox ri. Nat Rev Rheumatol. 2025 Jul;21(7):426-437. doi: 10.1038/s41584-025-01268-z. Epub 2025 Jun 10. Nat Rev Rheumatol. 2025. PMID: 40494962
Progressive multiple sclerosis.
Ontaneda D, Fox RJ. Ontaneda D, et al. Among authors: fox rj. Curr Opin Neurol. 2015 Jun;28(3):237-43. doi: 10.1097/WCO.0000000000000195. Curr Opin Neurol. 2015. PMID: 25887766 Free PMC article. Review.
2,877 results